Since the discovery of IRAK1 in 1996, preclinical studies have established its involvement in a spectrum of inflammatory diseases, including fibrotic diseases, metabolic disorders, arthritis, lupus, and sepsis. Here, IRAK1 is linked to systemic lupus erythematosus.